Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Administration of Evolocumab After Thrombolysis in Acute Ischemic Stroke
NCT07301372Phase 2Completed
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Start
- Oct 2025
- Primary completion
- Mar 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of evolocumab in ischemic stroke, sponsored by The Affiliated Hospital of Xuzhou Medical University. Started Oct 2025; status: completed.
02
Drugs
evolocumab
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT07301372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07301372.